Best capital-productivity profile in the listed Indian CRDMO peer set — that's what 72× is paying for.

Anthem prints 43.4% EBITDA against Syngene's 25%, Cohance's 19% and Piramal's 10%, and holds it through the 2022-23 biotech crash that halved Syngene's ROCE. Backward integration on the previously-Chinese-sourced semaglutide intermediate killed China dependency; Unit I/II run above 75% utilisation, so each new commercial molecule throws off 50%+ contribution. The ₹1,374 Cr net cash funds the ₹1,200 Cr Unit-IV greenfield while Piramal carries ~₹4,200 Cr of net debt — capital structure is itself a moat in this peer set.

The FY26 print the multiple is anchored to is partly working-capital release and forex.

• Inventory days fell 167 → 56 in one year with no narrative explanation, releasing roughly ₹430 Cr of working capital across FY24-FY26 — the single swing that funded the ₹637 Cr FY26 free cash flow. Sustainable FCF is closer to ₹400-450 Cr.
• ₹41 Cr of forex and RoDTEP sits inside the FY26 EBITDA classification; Q4 included ₹51 Cr of Other Income and the ESOP charge dropped ₹20 Cr year-on-year. Strip all three and underlying CRDMO EBITDA is closer to 38% — the FY24 trough management has stopped referencing.
• Q1 FY27 in early August is the test. Two consecutive quarters above 40% EBITDA after the cash-conversion cycle normalises back toward 150 days settles whether the step-up is structural. Below that, the listed-CRDMO median sits near 50×, well under spot.

The closer peer outprints Anthem 2.4×, and the gap is widening.

• Sai Life Sciences owns 34 commercial NCEs to Anthem's 14, 11 Phase 3 to Anthem's 6, and added two new large-pharma supply qualifications in FY26 — Anthem added zero from that cohort. Sai grew revenue 29%; Anthem cut FY26 guidance from "around 20%" to mid-teens in February before Q4 closed at +26%.
• Aragen Life Sciences IPO is the tape event. Goldman-backed, biologics-tilted, comparable scale, DRHP filing reportedly in progress. Aragen pricing below 55× on a commercial-molecule count above 25 compresses the listed-CRDMO median 15-25% in a single tape — no change to the underlying business.
• FY26 added four commercial molecules — the best annual net add in five years and bull's strongest single fact. Anthem needs three-to-four per year through FY29 to keep Sai Life's lead from widening to 3×; the 130-140 early-phase funnel is real, conversion velocity from six Phase-3 molecules is the variable.

Founders own 74.67% — alignment overwhelming, supervisory machinery brand-new and already tested.

• ₹127.68 Cr promoter "upside-sharing" payout votes 22-Jul-2026. Triggered by True North's 9-Mar-2026 exit clearing the 25%-IRR threshold; cash transfer from company treasury to the three founders. Decided by the ~25% public float — the same block that voted at IPO. A second such arrangement would reframe alignment.
• DavosPharma routed 14.28% of FY25 revenue — 54% of all North America — through a Selling-Shareholder-affiliated intermediary that escapes the related-party firewall on a definition technicality. Neoanthem intercompany loans ramped ₹23 Cr → ₹329 Cr in three years, 11.7% of FY25 assets.
• Three insider-trading code violations in five weeks (Oct-Nov 2025); 19-year General Counsel resigned 31-Mar-2026 with no public reason; auditor rotated from K.P. Rao to S.R. Batliboi (EY India) effective FY27. Big Four oversight starts exactly where it is needed — and after the FY26 books closed.

Four hard dates resolve the debate the multiple is leaning into.

• 22-Jul-2026 — AGM vote on the ₹127.68 Cr promoter payout. Dissent above 20% or an IiAS "against" recommendation triggers a governance discount the Street has not priced. Clean ratification closes the debate; a second upside-sharing structure surfacing in any subsequent disclosure does not.
• Early August — Q1 FY27 print. CRDMO segment EBITDA at or above 40% on +18% revenue confirms the Q4 step-up. A return of "lumpiness" language with segment margin under 40% confirms the bear's working-capital point and forces FY27 EPS estimates down from the ₹12.36 consensus.
• CY H2 2026 — BIOSECURE conference reconciliation; Aragen IPO. Senate NDAA includes BIOSECURE; House version omits it — conference preservation extends the Indian-CRDMO tailwind. Aragen pricing below 55× compresses the listed-CRDMO median in a single tape, independent of Anthem's operations.